BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for oncology, metabolic diseases and central nervous system degenerative diseases. It offers BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; developing BEBT-209, a CDK4/6 selective inhibitor for metastatic triple-negative breast cancer; and BEBT-109, a selective EGFR inhibitor designed for NSCLC. The company also develops BEBT-503, an oral, well-balanced pan-PPAR for metabolic diseases including diabetes and mash; BEBT-507, a GalNAc-siRNA drug for Polycythemia Vera (PV); and BEBT-701, a GalNAc-siRNA therapeutic for treatment of hypertension with co-existing hyperlipidemia. In addition, it provides BEBT-809, a small molecule inhibitor for obesity; BEBT-706, for ASCVD risk reduction; BEBT-720, for mash; BEBT-758, for the treatment of Parkinson's disease; BEBT-756, for Alzheimer's disease; BEBT-730, for hyperuricemia and gout; BEBT-733, for renal anemia/CKD; and BEBT-738, for diabetes. The company was founded in 2012 and is based in Guangzhou, China.